• Most Popular
  • Most Shared

Lundbeck sees £154 million Xenazine sales in 2012-15

COPENHAGEN
Tue Jul 7, 2009 5:53am EDT

Stocks

   

COPENHAGEN (Reuters) - The head of Danish pharmaceuticals group H. Lundbeck A/S (LUN.CO) said on Tuesday that he expected sales of the drug Xenazine to reach $250 million (154 million pounds) in 2012-2015.

Chief Executive Ulf Wiinberg also told Reuters that Lundbeck would have exclusive rights to Xenazine, a drug for a symptom associated with Huntington's disease, to 2016.

The remarks came after Lundbeck said it agreed to acquire UK-based drugs firm LifeHealth, the holder of the rights to the drug, for $147 million.

(Reporting by Peter Levring.


More from Reuters

Photo

Democrats secure 60th vote on health bill

WASHINGTON (Reuters) - Senate Democrats reached a compromise on Saturday with a holdout senator that secured the 60 votes they need to pass a broad healthcare overhaul sought by President Barack Obama.

» More Top News
A woman shops at a Sam's Club store, a division of Wal-Mart Stores, in Bentonville, Arkansas June 4, 2009. REUTERS/Jessica Rinaldi

The food-stamp economy

On the last day of every month, shoppers at Walmart load their carts with food and household items and wait for the midnight hour. Is this the new normal in America?  Full Article 

U.S.
Two men shake hands in a file photo. REUTERS/File

Let's make a deal

The battered M&A sector will make a tepid recovery in the coming year and three hot sectors will lead the way, according to a Thomson Reuters analysis.  Full Article 

Global Deals Review